P38 MAPK inhibitors: A patent review (2012-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 5, 2014, Pages 535-554

  Bühler, Stefanie ^a   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Allosteric inhibitor; Alzheimer s disease; Asthma; BAY 73 4506; BMS 582949; Cancer; Chronic obstructive pulmonary disease; Competitive inhibitor; DFG out; Downstream effectors; Drug combination; Dual action p38 inhibitor; Glycine flip; Inflammatory diseases; Linear binders; Non small cell lung carcinoma; P38 MAPK; P38 MK2 inhibitors; Proinflammatory cytokine; Pulmonary diseases; Rheumatoid arthritis; TNF ; Upstream kinase; VX 745

Indexed keywords

ALPRENOLOL; CARBONYL DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OXYGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR;

ALZHEIMER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG TARGETING; HINGE REGION; HUMAN; NEOPLASM; NONHUMAN; PATENT; REVIEW; RHEUMATOID ARTHRITIS; TREND STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG INDUSTRY; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; ARTHRITIS, RHEUMATOID; DRUG INDUSTRY; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84898981377     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.894977     Document Type: Review

References (99)

1. Young PR. Perspective on the discovery and scientific impact of p38 MAP kinase. J Biomol Screen 2013;18:1156-63
2. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
3. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signaling. Biochem J 2010;429:403-17
4. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996;271:17920-6
5. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28:286-95
6. Li Z, Jiang Y, Ulevitch RJ, et al. The primary structure of p38gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun 1996;228:334-40
7. Fischer S, Koeberle SC, Laufer SA. p38alpha mitogen-activated protein kinase inhibitors, a patent review (2005 - 2011). Expert Opin Ther Pat 2011;21:1843-66
8. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16
9. Millan DS, Bunnage ME, Burrows JL, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54:7797-814
10. Hammaker D, Firestein GS. Go upstream, young man: lessons learned from the p38 saga. Ann Rheum Dis 2010;69:i77-82
11. ClinicalTrials.gov http:// www.clinicaltrials.gov [Last accessed 23 November 2013
12. Flynn Gary A. Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors. WO2013022766; 2013
13. Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009;9:655-76
14. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005;12(25):2979-94
15. Okram B, Nagle A, Adrian FJ, et al. A general strategy for creating inactiveconformation abl inhibitors. Chem Biol 2006;13:779-86
16. Angell RM, Angell TD, Bamborough P, et al. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett 2008;18:4433-7
17. Wrobleski ST, Lin S, Hynes J, et al. Synthesis and SAR of new pyrrolo[2,1-f] [1,2,4]triazines as potent p38alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2008;18:2739-44
18. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1046-51
19. Fitzgerald CE, Patel SB, Becker JW, et al. Structural basis for p38alpha MAP kinase quinazolinone and pyridolpyrimidine inhibitor specificity. Nat Struct Biol 2003;10:764-9
20. Proqinase. Available from: www. proqinase.com [Last accessed at 23 November 2013]
21. Respivert. Available from: www.respivert. com [Last accessed at 13 November 2013]
22. Respivert - treatment of asthma and COPD. Available from: http://www. imperialinnovations.co.uk/ventures/casestudies/ respivert-treatment-asthma- andcopd/ [Last accessed at 13 November 2013]
23. Centocor Ortho Biotech, Inc. Acquires RespiVert Ltd, Strengthens Pulmonary Focus. 2010. Available from: http://www.prnewswire.com/newsreleases/ centocor-ortho-biotech-incacquires- respivert-ltd-strengthenspulmonary- focus-95293879.html [Last accessed at 13 November 2013]
24. Respivert Ltd. 1-pyrazolyl-3-(4-((2 - anilinopyrimidin-4-yl)oxy) napththalen-1- yl)ureas as P38 map kinase inhibitors. WO2013050756; 2013
25. Respivert Ltd. P38 MAP kinase inhibitors. US20130012512; 2013
26. Respivert Ltd. 1-Pyrazolyl-3-(4-((2- anilinopyrimidin-4-yl)oxy) naphthalen-1- yl)ureas as p38 MAP kinase inhibitors. EP2578582; 2013
27. Respivert Ltd. 1-pyrazolyl-3-(4-((2 - anilinopyrimidin-4-yl)oxy) napththalen-1- yl)ureas as P38 MAP kinase inhibitors. WO2013050757; 2013
28. Respivert Ltd. Novel compounds. US20130040995; 2013
29. Respivert Ltd. P38 MAP kinase inhibitors. US20130040962; 2013
30. Respivert Ltd. Pyrazole P38 MAP kinase inhibitors. US20130029990; 2013
31. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2011;9:268-72
32. Irusen E, Matthews JG, Takahashi A, et al. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-57
33. Respivert Ltd. Pyrazole P38 MAP kinase inhibitors. EP2556065; 2013
34. Respivert Ltd. P38 MAP kinase inhibitors. EP2556068; 2013
35. Respivert Ltd. Pyrazolyl ureas as P38 MAP kinase inhibitors. EP2556067; 2013
36. Confluence Life Sciences, Inc. Substituted pyridine urea compounds. US20120142708; 2012
37. Confluence Life Sciences, Inc. Substituted pyrimidine urea compounds. WO2012078687; 2012
38. Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl- pyrimidinyl compounds. US20130143906; 2013
39. Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl- pyrimidinyl compounds. US20130143906; 2013
40. Goldstein DM, Kuglstatter A, Lou Y, et al. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010;53:2345-53
41. Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds. US20120142696; 2012
42. Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds. US20120142709; 2012
43. Selness SR, Devraj RV, Devadas B, et al. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 2011;21:4066-71
44. Devadas B, Selness SR, Xing L, et al. Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors. Bioorg Med Chem Lett 2011;21:3856-60
45. Selness SR, Devraj RV, Monahan JB, et al. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase. Bioorg Med Chem Lett 2009;19:5851-6
46. Selness SR, Boehm TL, Walker JK, et al. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase. Bioorg Med Chem Lett 2011;21:4059-65
47. Confluence Life Sciences, Inc. Methyl/ difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds. US20130274272; 2013
48. Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl- pyrimidinyl compounds. US20130143906; 2013
49. Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl- pyrimidinyl compounds. US20130143906; 2013
50. Chiesi Farmaceutici S.P.A. Kinase inhibitors. WO2013083606; 2013
51. Chiesi Farmaceutici S.P.A. Kinase inhibitors. WO2013083604; 2013
52. Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4- tetrahydronaphtalen-1- yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract. WO2013083206; 2013
53. Chopra P, Kanoje V, Semwal A, et al. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008;17:1411-25
54. Millan DS. What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease? Future Med Chem 2011;3:1635-45
55. Pulmagen Therapeutics Inflamma. Triazolopyridine derivatives as P38 MAP kinase inhibitors. WO2010094956; 2010
56. Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives and their therapeutic use. US20120088763; 2012
57. Aiguade J, Balague C, Carranco I, et al. Novel triazolopyridylbenzamides as potent and selective p38alpha inhibitors. Bioorg Med Chem Lett 2012;22:3431-6
58. McClure KF, Abramov YA, Laird ER, et al. Theoretical and Experimental Design of Atypical Kinase Inhibitors: application to p38 MAP Kinase. J Med Chem 2005;48:5728-37
59. Bayer Healthcare LLC. Inhibition of P38 kinase activity using substituted heterocyclic ureas. US20120149706; 2012
60. Bayer Healthcare LLC. Inhibition of P38 kinase activity using substituted heterocyclic ureas. US20120046290; 2012
61. Dumas J, Hatoum-Mokdad H, Sibley RN, et al. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg Med Chem Lett 2002;12:1559-62
62. Dumas J, Sibley R, Riedl B, et al. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett 2000;10:2047-50
63. Dumas J, Hatoum-Mokdad H, Sibley R, et al. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg Med Chem Lett 2000;10:2051-4
64. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72
65. Bayer Healthcare LLC. Inhibition of P38 kinase using symmetrical and unsymmetrical diphenyl ureas. US20120270878; 2012
66. Bayer Pharmaceuticals Corp. Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. WO2005009961; 2005
67. Bayer Healthcare LLC. Fluro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. US20130131122; 2013
68. Bayer Healthcare LLC. Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. WO2012012404; 2012
69. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55
70. An Open-label, multi-center, nonrandomized Phase Ib study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 Regorafenib, administered in combination with Pemetrexed and Cisplatin in patients with Advanced Nonsquamous Non Small Cell Lung. Available from: http://trialfinder. bayerscheringpharma.de/html/pdf/ 14458-Study-Synopsis-CTP.pdf [Last accessed at 18 November 2013]
71. Astrazeneca UK Ltd. Pyrazinone derivatives and their use in the treatment of lung diseases. WO2009001132; 2009
72. Astrazeneca UK Ltd. Pharmaceutical product comprising a P38 kinase inhibitor and a second active ingredient. US2012028941; 2012
73. Astrazeneca UK Ltd. Novel combinations. WO2012046050; 2012
74. Astrazeneca UK Ltd. Compound. WO2012085582; 2012
75. Astrazeneca UK Ltd. New compound. WO2012085583; 2012
76. Bristol-Myers Squibb. Pyrrolo-triazine aniline compounds useful as kinase inhibitors. WO2003090912; 2003
77. Bristol-Myers Squibb. Tablet formulation for P38 inhibitor and method. US20120035177; 2012
78. Liu C, Lin J, Wrobleski ST, et al. Discovery of 4-(5- (cyclopropylcarbamoyl)-2- methylphenylamino)-5-methyl-Npropylpyrrolo[ 1,2-f][1,2,4]triazine-6- carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem 2010;53:6629-39
79. Bristol-Myers Squibb. BMS-582949 for the treatment of resistant rheumatic disease. WO2012031057; 2012
80. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology 2011;50:1542-50
81. Schieven G, Zhang R, Pitt S, et al. BMS-582949 is a dual action p38 kinase inhibitor well suited to avoid resistance mechanisms that increase p38 activation in cells. Presented at the 2010 Congress American College of Rheumatology. Arthritis Rheum 2010;62:S629-30
82. Emerging Oral Biologic Therapies for Rheumatoid Arthritis. Available from: http://lmt.projectsinknowledge.com [Last accessed at 23 November 2013]
83. Novartis AG. 5-membered heterocyclebased P38 kinase inhibitors. US20120264801; 2012
84. Novartis AG. 5-membered heterocyclebased P38 kinase inhibitors. US20130172352; 2013
85. Novartis AG. Use of pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease. WO2013139809; 2013
86. Eli Lilly and Co. Kinase inhibitors. WO2005075478; 2005
87. de Dios A, Shih C, Lopez de Uralde B, et al. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 2005;48:2270-3
88. Mader M, de Dios A, Shih C, et al. Imidazolyl benzimidazoles and imidazo [4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett 2008;18:179-83
89. Eli Lilly and Co. Oxazolo[5, 4 -B] pyridin-5-yl compounds and their use for the treatment of cancer. WO2012074761; 2012
90. EIP Pharma, LLC. Compositions and methods for treating Alzheimers disease. WO2012154814; 2012
91. Cellworks Research India Private Ltd. Compositions, process of preparation of said compositions and method of treating cancer. WO2013086002; 2013
92. Helmholtz-Zentrum Fur Infektionsforschung Gmbh. Medicament for treatment of liver cancer. WO2013007708; 2013
93. Translational Genomics Research Institute. Methods of treating memory loss and enhancing memory performance. US2012245188; 2012
94. Joint Stock Co. Pharmasyntez. Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process. WO2012156938; 2012
95. The Trustees of Columbia University in the city of New York. CaMKII, IP3R, calcineurin, P38 and MK2/3 inhibitors to treat metabolic disturbances of obesity. WO2013033657; 2013
96. Universidad Autonóma de Madrid. Drugs for inhibiting P38 and uses thereof. WO2013064714; 2013
97. Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 2013;73:857-74
98. Alten R. Intracellular targets - current data on effectiveness and safety profile. Z Rheumatol 2013;72:867-72
99. p38 MAPK Pathway. Available from: http://www.novusbio.com/ p38mapkpathway.html [Last accessed 26 November 2013]